Patients with diabetes mellitus (DM) are prone to a diffuse and accelerated form of coronary artery disease (CAD), which in turn is a major cause of cardiac-related morbidity and 
INTRODUCTION
Over the last decades, the prevalence of diabetes mellitus (DM) has significantly increased worldwide [1] . Coronary artery disease (CAD) is a major cause of morbidity and mortality among patients with DM. Compared to individuals without diabetes, those with diabetes have a higher prevalence of CAD, present at an earlier age, and have a greater extent of coronary atherosclerosis [2] .
Due to the aggressive form of CAD, a large proportion of diabetic patients require intensive medical treatment and surgical or percutaneous coronary revascularization, and therefore optimal decision-making on medical and revascularization strategies of significant CAD is crucial to obtain better long-term outcomes in such patients.
For patients with diabetes requiring coronary revascularization, coronary artery bypass grafting (CABG) has been considered the preferred revascularization strategy because of concerns regarding higher risk of restenosis and ischemic cardiovascular complications, and uncertainty of very long-term durability of percutaneous coronary intervention (PCI) [3] . However, with rapid advancements of novel PCI devices, techniques, and adjunctive drug therapy, clinical results of PCI for patients with diabetes have been markedly improved, and also newer technologies are continuously developing to enhance clinical outcomes in diabetic patients with complex clinical and angiographic characteristics [4] .
In this review of the literature, the key clinical studies comparing medical, percutaneous, or surgical management for diabetic patients with CAD have been summarized, and the authors also compare PCI outcomes among several stent types in patients with diabetes. This review provides valuable information for optimal selection of revascularization strategy as well as PCI devices for patients with diabetes with higher clinical and angiographic risk profiles. [12] .
MATERIALS AND METHODS
Similarly, observation registry with drug-eluting stent (DES) showed that 3-year mortality was significantly higher in patients with diabetes than in those without (17.3% vs. 7.8%) [13] .
Some studies suggest that the clinical impact of diabetes may vary among various ethnic populations [17] [18] [19] .
Optimal Treatment Selection: Medical
Versus Revascularization
Optimal treatment for patients with both type 2 DM and stable CAD has been controversial. The 30 .5%, P = 0.01), mainly driven by markedly fewer incidences of nonfatal MI in the revascularization group than in the medical therapy group (7.4% vs. 14.6%). vs. 20.6%, P = 0.0003) [15] . The diabetic subgroup analysis (n = 208) of the Arterial Revascularization Therapies Study (ARTS) Trial comparing BMS and CABG for multivessel CAD showed that PCI was significantly associated with a higher rate of repeat revascularization, but hard clinical endpoints were not different among the two revascularization strategies at 5-year follow-up [16] . A pooled analysis of individual patient data from 10 randomized trials suggested that among patients with diabetes, mortality was lower in the surgical group (n = 615) than in the PCI group (n = 618) (23% vs. 29%, hazard ratio [HR] = 0.70, 0.56-0.87) [17] . In contrast, registry data showed that patients with diabetes and multivessel disease had non-significant adjusted outcomes (death: HR = 0.97, P = 0.75, death or MI: HR = 0.84, P = 0.07) following PCI with DES (n = 3,256) compared with CABG (n = 2,844) [18] . 
First-Generation DES: SES Versus PES
The relative efficacy and safety of SES and PES in patients with diabetes has been evaluated in several clinical studies. The direct and indirect network analysis showed that there was no difference found in death or MI between SES and PES in patients with diabetes, but the rate of repeat revascularization was lower after use of SES compared with PES [22] . In contrast, a subsequent meta-analysis of over 12,000 patients with diabetes including several randomized controlled trials (RCT) and observational studies showed that the risks of MACE and repeat revascularization were similar between PES and SES [24] . In a subset of 13 RCTs, the rates for MACE (PES: 15.4% vs. SES:
12.9%) and TLR (PES: 8.6% vs. SES: 7.6%) were similar between two stents, and in subset of 16 registries, the rates for MACE (PES: 10.1% vs. SES: 11.9%) and target-vessel revascularization (TVR) (PES: 5.8% vs. SES: 7.2%) were also similar. Recently, long-term results of a metaanalysis including six RCTs comparing SES and PES in diabetic population showed that the use of SES was significantly associated with 35% reduction of TLR compared to PES, but there were no differences of safety outcomes in terms of death or MI, and stent thrombosis at a median follow-up of 4 years [25] .
Second-Generation DES
Since early-generation DES had been widely used and long-term safety issues had been Merged analyses of these clinical trials compared the relative treatment effect of EES and PES according to the diabetic status [34] .
Compared to the remarkable benefit of EES over PES in patients without diabetes, no significant differences of clinical outcomes were seen between the two stent types in patients with diabetes. A significant interaction was found between the presence of diabetes and stent type for the 2-year occurrence of MI (P = 0.01), stent thrombosis (P = 0.0006), and ischemia-driven TLR (P = 0.02). Further studies might be required to explain the underlying mechanism of diabetic-related interaction on clinical outcomes according to different DES types.
Randomized comparisons showed similar outcomes for EES and SES with respect to rates of death, MI, and repeat revascularization, and these results were also maintained in diabetic population [35, 36] . A recent network meta-analysis comparing outcomes with various DES (SES, PES, EES, and ZES) or BMS in 22,844 patients with diabetes showed that currently used DESs are more efficient at reducing the risk of TLR without compromising safety outcomes, as compared with BMS [42] . There are considerable differences in the relative efficacy and safety profiles of various DESs and EES seems to be the most efficient and the safest of the currently available DES in patients with diabetes. Figure 2 illustrates the probability of several DES and BMS producing the best outcomes in terms of efficacy and safety endpoints for patients with 
Adjunctive Drug Therapies in Diabetic
Patients Receiving PCI
The effect of glycemic control on PCI outcomes among diabetic patients has been investigated in previous study [46] . This study suggested that has been evaluated in two small randomized trials using pioglitazone [47] or rosiglitazone [48] and lower rates of angiographic restenosis were found in the experimental group. However, due to limited sample size and lack of clinical benefit, larger studies are needed for definite conclusions.
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor reduces the risk of ischemic events after stent placement. However, as compared with patients without diabetes, the efficacy of antiplatelet agents is significantly reduced in patients with diabetes, due to platelet hyper-reactivity and relatively poor response to antiplatelet therapy [49, 50] . Until now, several studies testing novel antiplatelet agents suggested that platelet inhibition could be further enhanced among patients with diabetes receiving PCI. Results of diabetic subgroup analyses from major pharmacologic clinical trials comparing prasugrel [51, 52] , ticagrelor [53] , high-dose clopidogrel [54] , and vorapaxar [55] , as compared to standard clopidogrel therapy are shown in Table 2 .
Overall, although it was not always statistically significant, treatment effect favored new antiplatelet agents or regimens over standard regimen. 
CONCLUSIONS
For patients with diabetes with significant CAD, the decision when and how to proceed to coronary revascularization should be based on multiple parameters including patient characteristics, comorbidities, clinical presentation, coronary anatomy and lesion complexity, ischemic burden, left ventricular function, and patients preference. Since decision-making in patients with diabetes is frequently complicated, such a decision is reasonable to be made after discussion in a multidisciplinary ''heart team.'' Based on compelling evidence of the FREEDOM Trial, the threshold for selecting CABG over PCI would be lower in patients with diabetes than in patients without.
With marked advances of stent device technology and adjunctive pharmacology, PCI Table 2 Summary of novel antiplatelet strategies in diabetic population with acute coronary syndrome trials 
